abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

이 페이지는 한국어로 제공되지 않으며 English로 표시됩니다.

기사

2005년 8월 13일

저자:
M G Arun, Financial Express [India]

Interview: Harvey E. Bale [Director General, International Federation of Pharmaceutical Manufacturers & Associations] - Patents, access to drugs is the issue

All countries have patent safeguards and have the right and ability to implement compulsory licensing in emergency circumstances...It is important for India and the rest of the world to have a good balance between implementation of innovation policies and those that give better access to medicine. There is no conflict between a patent system and the public’s access to medicines. [refers to Dr Reddy’s, Ranbaxy]